{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=27&state=Ohio", "query": { "state": "Ohio", "city": "Columbus", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 10847, "total_pages": 1085, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=28&state=Ohio&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=26&state=Ohio&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T06:09:35.180Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00507416", "title": "Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 502, "start_date": "2007-06", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-05-01", "last_synced_at": "2026-11-03T06:09:35.180Z", "location_count": 234, "location_summary": "Birmingham, Alabama • Casa Grande, Arizona • Sedona, Arizona + 205 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00507416" }, { "nct_id": "NCT00412984", "title": "Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Atrial Flutter" ], "interventions": [ { "name": "warfarin", "type": "DRUG" }, { "name": "apixaban", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20976, "start_date": "2006-12-31", "completion_date": "2011-05-25", "has_results": true, "last_update_posted_date": "2018-07-03", "last_synced_at": "2026-11-03T06:09:35.180Z", "location_count": 284, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 206 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00412984" }, { "nct_id": "NCT05086016", "title": "Growth Trial: Study of the Renata Minima Stent", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Coarctation of the Aorta", "Pulmonary Artery Stenosis" ], "interventions": [ { "name": "Catheterized Stenting", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Renata Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 42, "start_date": "2021-01-14", "completion_date": "2028-03-30", "has_results": true, "last_update_posted_date": "2025-03-25", "last_synced_at": "2026-11-03T06:09:35.180Z", "location_count": 7, "location_summary": "Los Angeles, California • Boston, Massachusetts • Cincinnati, Ohio + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086016" }, { "nct_id": "NCT00031447", "title": "Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Herpes Simplex" ], "interventions": [ { "name": "Acyclovir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "28 Days", "sex": "ALL", "summary": "Up to 28 Days" }, "enrollment_count": 29, "start_date": "1999-08", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-11-03T06:09:35.180Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031447" }, { "nct_id": "NCT00342849", "title": "Treatment of Lead-Exposed Children Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lead Exposure" ], "interventions": [ { "name": "Succimer", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Environmental Health Sciences (NIEHS)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "33 Months", "sex": "ALL", "summary": "12 Months to 33 Months" }, "enrollment_count": 780, "start_date": "1994-07-15", "completion_date": "2015-06-10", "has_results": false, "last_update_posted_date": "2018-04-05", "last_synced_at": "2026-11-03T06:09:35.180Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Newark, New Jersey • Columbus, Ohio + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Newark", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00342849" }, { "nct_id": "NCT00978458", "title": "Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Brain and Central Nervous System Tumors", "Neurotoxicity" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 540, "start_date": "2009-11-17", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-03T06:09:35.180Z", "location_count": 168, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00978458" }, { "nct_id": "NCT01258855", "title": "Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma", "Recurrent Melanoma", "Stage III Cutaneous Melanoma AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7" ], "interventions": [ { "name": "Aldesleukin", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Ziv-Aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": 84, "start_date": "2011-01-18", "completion_date": "2018-03-29", "has_results": true, "last_update_posted_date": "2019-05-10", "last_synced_at": "2026-11-03T06:09:35.180Z", "location_count": 21, "location_summary": "Duarte, California • Sacramento, California • South Pasadena, California + 14 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "South Pasadena", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01258855" }, { "nct_id": "NCT00538434", "title": "Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "Reslizumab", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Ception Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "5 Years to 18 Years" }, "enrollment_count": 227, "start_date": "2008-03", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2016-09-02", "last_synced_at": "2026-11-03T06:09:35.180Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Hayward", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538434" }, { "nct_id": "NCT03448692", "title": "A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Focal Segmental Glomerulosclerosis (FSGS)" ], "interventions": [ { "name": "PF-06730512", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2018-10-15", "completion_date": "2023-02-14", "has_results": true, "last_update_posted_date": "2024-04-18", "last_synced_at": "2026-11-03T06:09:35.180Z", "location_count": 56, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03448692" }, { "nct_id": "NCT02177136", "title": "Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Sclerosing Cholangitis (PSC)" ], "interventions": [ { "name": "Obeticholic Acid (OCA)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 77, "start_date": "2015-02-09", "completion_date": "2018-03-22", "has_results": true, "last_update_posted_date": "2021-07-08", "last_synced_at": "2026-11-03T06:09:35.180Z", "location_count": 33, "location_summary": "Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02177136" } ] }